Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Large drugmakers are getting interested in small molecules that target RNA, and they are turning to Skyhawk Therapeutics for help. The start-up will work with Merck & Co. to develop molecules that modify RNA splicing to treat neurological diseases and cancer. And Biogen is expanding a collaboration in which Skyhawk is developing therapies for neurological disorders, including multiple sclerosis and spinal muscular atrophy. Skyhawk will receive undisclosed immediate and milestone payments from both partners.
This article has been sent to the following recipient: